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Iron homeostasis is essential for life and health. In this issue of Cell Metabolism, Moroishi and colleagues
(2011) show that FBXL5, an iron sensor in an ubiquitin ligase complex, keeps cellular iron in balance by
promoting the degradation of IRP2 in vivo.Iron is an abundant metal in our environ-
ment that has been co-opted by biological
processes that take advantage of its
ability to gain and lose electrons as it
converts between Fe3+ and Fe2+ oxidation
states. Theproperty thatmakes ironuseful
also makes it toxic; free iron catalyzes


















Figure 1. Regulation of Cellular Iron Homeostasis by
IREs/IRPs
(A) Cellular iron uptake involves binding of iron-loaded trans-
ferrin (Fe-TF) to cell surface transferrin receptors (TFR) for
endocytosis (not depicted) or transmembrane transport via
divalent metal transporter 1 (DMT1). Inside normal cells most
iron is stored in ferritin or utilized by iron-containing proteins,
and a small fraction contributes to the labile iron pool (LIP).
Iron is released from the cell through the transmembrane
transporter ferroportin. Outside the cell most iron exists in
the Fe3+ (ferric) form, but the LIP includes Fe2+ (ferrous) iron.
Each of the cellular proteins in this diagram has an IRE in its
mRNA; the positions of the IREs are shown in parentheses.
(B) Arrows indicate the effects of increased IRP activity due to
loss of FBXL5: proteins involved in iron import are increased;
proteins involved in iron storage and export are decreased.
This results in enlargement of the LIP.that wreak havoc on cellular com-
ponents. Iron homeostasis ensures
that physiological needs are met
without accumulating free iron. In
this issue, Moroishi and colleagues
show that F box and leucine-rich
repeat protein 5 (FBXL5), an iron-
sensing subunit of an SCF-type
ubiquitin ligase complex, is critical
in this process (Moroishi et al., 2011).
Disruption of iron homeostasis
has clinical consequences. Iron de-
ficiency causes anemia because
iron is the active cofactor of hemo-
globin, and erythropoiesis has pri-
ority use of body iron stores. At the
other extreme, iron surfeit causes
abnormal tissue iron deposition
and consequent cellular damage.
Investigation of genetic lesions that
promote iron deficiency or iron over-
load in humans and mice has en-
riched our understanding of genes
and proteins important in iron ho-
meostasis (reviewed in Andrews,
2008). Hereditary iron overload (he-
mochromatosis) results from pertur-
bation of the production or function
of hepcidin, a peptide hormone
that inactivates ferroportin, the
major transporter responsible for
cellular iron release. The hepcidin/
ferroportin axis is an elegant control
mechanism: modulation of iron re-
lease from intestinal epithelial cells
regulates iron absorption, andmodulation of iron release from storage
depots in hepatocytes and macrophages
maintains an appropriate level of the
metal in the circulation (Figure 1A). In
hemochromatosis, iron overload results
from uninhibited ferroportin activity.
Individual cells must also maintain iron
balance. A mechanism for posttranscrip-Cell Metabolism 14, Stional control of expression of key pro-
teins involved in iron transport and
storage was initially described in cultured
cells and subsequently confirmed in vivo
(reviewed in Hentze et al., 2010). Stem-
loop structures in noncoding portions of
mRNAs act as iron-regulatory elements
(IREs), inhibiting mRNA translation (50eptemIREs) or promoting mRNA stability
(30 IREs) by interacting with iron-
regulatory proteins (IRPs). IRPs
bind IREs when the intracellular
labile iron pool is depleted but are
inactivated and degraded when
iron is abundant. Studies in cultured
cells showed that IRP degradation is
triggered by FBXL5, which has an
iron-binding hemerythrin-like do-
main (Salahudeen et al., 2009; Va-
shisht et al., 2009). Moroishi and
colleagues have now confirmed
this role of FBXL5 in vivo in global
and liver-specific knockout mice
(Moroishi et al., 2011).
Mice lacking FBXL5 die early in
embryogenesis, apparently from
deleterious effects of free iron accu-
mulation. To prove that the proximal
cause is uncontrolled IRP activity,
the investigators took advantage of
a second knockout mouse lacking
IRP2. Their strategy is analogous to
that used by Finberg and colleagues
toshowthataserineprotease inhibits
a signaling pathway important for
hepcidin transcription (Finberg et al.,
2010). In both cases, depletion of
the target rescues the phenotype
caused by knockout of the protein
that controls its degradation. Here,
Moroishi et al. crossed Fbxl5/
mice to mice lacking Irp2 and
showed that loss of Irp2 masked the
Fbxl5/ phenotype. This indicatesber 7, 2011 ª2011 Elsevier Inc. 281
Cell Metabolism
Previewsthat the primary (perhaps exclusive) role of
FBXL5 is to regulate IRPs to keep cellular
iron content under control.
Moroishi et al. next asked what effects
loss of FBXL5 would have later in devel-
opment, focusing on the liver, which
serves as the body’s clearinghouse for
iron. Mice lacking FBXL5 in the liver
were viable but had steatosis and hepatic
inflammation. Strikingly, when fed a high-
iron diet, the liver-specific knockout ani-
mals died very quickly, with evidence of
oxidative stress and severe liver failure,
which was attenuated with an antioxidant
treatment. In addition to playing a crucial
role in liver iron homeostasis, it is tempting
to speculate that FBXL5 might also regu-
late iron homeostasis in other tissues,
particularly in neuronal cells damaged in
neurodegenerative diseases.
These findings may have potential
implications for human diseases. Mo-
roishi and colleagues suggest that muta-
tions in FBXL5 might explain rare cases
of hemochromatosis that are not attribut-
able to mutations in any of the previously
described disease genes. Nearly all cases
have a known genetic cause, with identifi-
able mutations in HFE, TFR2 (transferrin
receptor 2), HFE2 (hemojuvelin), HAMP
(hepcidin), or SLC40A1 (ferroportin). The
unifying feature of these disorders is
perturbation of the synthesis or activity
of hepcidin (reviewed in Andrews, 2008).
But none causes fetal loss, and even the
most severe do not become clinically
apparent until late childhood. Mouse
models of genetic hemochromatosis282 Cell Metabolism 14, September 7, 2011 ªhave provided insight into the pathophys-
iology. In contrast to Fbxl5/ mice, all of
the hemochromatosis mice are viable and
none has significant prenatal iron over-
load—a heterozygous mother can main-
tain iron homeostasis in her affected
fetus. Furthermore, the hemochromatosis
mutants can be maintained on a high-iron
diet without obvious adverse effects.
Why should loss of FBXL5 cause a
more severe phenotype than has been
observed in other mouse models of iron
overload? The authors suggest that mice
lacking Fbxl5 have excess ferrous (Fe3+)
iron, leading to oxidative stress. In other
iron overload conditions, cells can store
Fe2+ iron in ferritin, sequestering it in a
relatively safe form. But unchecked IRP
activity inhibits ferritin synthesis, abro-
gating this defense. In the absence of
FBXL5, IRP activity leads to increased
iron import, decreased iron export, and
decreased iron storage (Figure 1B)—in
other words, activation of measures to
deal with iron deficiency when cells are
iron replete.
Though loss of FBXL5 results in a dis-
order that differs from classical hemo-
chromatosis, there is one disease, termed
neonatal hemochromatosis (NH), which
does have features similar to the pheno-
type of Fbxl5/ mice. Infants with NH
are born with dramatic liver failure and
iron deposition in a pattern similar to
hemochromatosis and usually die within
the first month of life. Oxidative stress
may be a factor in the severity of the dis-
order—antioxidant cocktails have been2011 Elsevier Inc.reported to have some utility (Whitington,
2007). The prevailing hypothesis is that
NH is an alloimmune disease, because
the disease recurs when mothers of
affected infants have children with
other partners, and survivors do not
have hemochromatosis later in life (Whi-
tington, 2007). Prenatal treatment with
immunoglobulin has been reported to be
of benefit. However, no antigen has
been identified to explain the presumed
alloreactivity, and the pathogenesis is
incompletely understood. The striking
similarity between Fbxl5/ mice and NH
patients may be an important clue to the
etiology of this enigmatic and devastating
disease.REFERENCES
Andrews, N.C. (2008). Blood 112, 219–230.
Finberg, K.E., Whittlesey, R.L., Fleming, M.D., and
Andrews, N.C. (2010). Blood 115, 3817–3826.
Hentze, M.W., Muckenthaler, M.U., Galy, B., and
Camaschella, C. (2010). Cell 142, 24–38.
Moroishi, T., Nishiyama, M., Takeda, Y., Iwai, K.,
and Nakayama, K. (2011). Cell Metab. 14, this
issue, 339–351.
Salahudeen, A.A., Thompson, J.W., Ruiz, J.C., Ma,
H.W., Kinch, L.N., Li, Q., Grishin, N.V., and Bruick,
R.K. (2009). Science 326, 722–726.
Vashisht, A.A., Zumbrennen, K.B., Huang, X.,
Powers, D.N., Durazo, A., Sun, D., Bhaskaran, N.,
Persson, A., Uhlen, M., Sangfelt, O., et al. (2009).
Science 326, 718–721.
Whitington, P.F. (2007). Semin. Liver Dis. 27,
243–250.
